Related Experiment Videos
[Clinical evaluation of cefuzonam in pediatrics]
Insights
Cefuzonam (CZON), an injectable cephalosporin, showed a 75% efficacy rate in treating pediatric infections, with no severe side effects observed. Surgical intervention was necessary for some complex cases.
Area of Science:
- Infectious Diseases
- Pediatric Medicine
- Pharmacology
Context:
- Pediatric infections pose significant health challenges.
- Novel antimicrobial agents are crucial for effective treatment.
- Cephalosporins are a key class of antibiotics used in pediatric care.
Purpose:
- To evaluate the clinical efficacy and safety of Cefuzonam (CZON), a new injectable cephalosporin.
- To assess CZON's effectiveness in treating various pediatric infections.
- To document any adverse events associated with CZON administration.
Summary:
- Cefuzonam was administered to 12 pediatric patients with infections including tonsillitis, pneumonia, nephropyelitis, lymphadenitis, thyroiditis, and vulvar abscess.
- Dosages ranged from 42.9 to 93.3 mg/kg/day intravenously for 6-12 days.
- An overall clinical efficacy rate of 75.0% was observed (4 excellent, 5 good, 3 poor).
- Poor efficacy was noted in complex cases requiring surgical intervention.
- No significant clinical side effects were reported, with minor laboratory abnormalities in some patients.
Impact:
- Cefuzonam demonstrates potential as a treatment option for pediatric infections.
- The study highlights the importance of considering adjunctive therapies like surgery for refractory cases.
- Further research may explore CZON's role in specific pediatric infectious disease management.
Abstract:
Cefuzonam (L-105, CZON), a new injectable cephalosporin, was used in 12 pediatric patients with infections. The following is a summary of the results: The 12 cases included 3 cases of tonsillitis (pathogen: Haemophilus parainfluenzae in 1 case, Haemophilus influenzae in 2 cases), 4 cases of pneumonia (Staphylococcus aureus in 1 case, pathogen unknown in 3 cases), 2 cases of nephropyelitis (Escherichia coli in 2 cases), 1 case of purulent lymphadenitis (pathogen unknown), 1 case of purulent thyroiditis (mixed infection of Streptococcus milleri, Haemophilus aphrophilus and anaerobes), and 1 case of vulvar abscess (E. coli). Dose levels of CZON were 42.9 approximately 93.3 mg/kg/day divided into 3 or 4 times and the drug was intravenously injected for 6 to 12 days. Clinical efficacies were excellent in 4 cases, good in 5 cases, and poor in 3 cases, with the efficacy rate of 75.0%. The 3 cases with poor efficacy consisted of 1 case each of pneumonia complicated with chronic granulomatosis, purulent thyroiditis associated with piriform recess fistula, and purulent lymphadenitis of armpit developed after surgical operation of congenital heart disease. In the first 2 cases satisfactory efficacy was not obtained by chemotherapy alone, and complete cure was seen after surgical operation. Side effects were not observed clinically. One case each of slight prolongation of prothrombin time and transient elevations of GOT and GPT values were noted but no severe abnormalities were found in laboratory tests.(ABSTRACT TRUNCATED AT 250 WORDS)